Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure

Muntinga, HJ., vanderVring, JAFM., Niemeyer, MG., vandenBerg, F., Knol, HR., Bernink, PJLM., vanderWall, EE., Blanksma, PK. & Lie, KI., May-1996, In : Journal of Cardiovascular Pharmacology. 27, 5, p. 652-656 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • HJ Muntinga
  • JAFM vanderVring
  • MG Niemeyer
  • F vandenBerg
  • HR Knol
  • PJLM Bernink
  • EE vanderWall
  • PK Blanksma
  • KI Lie

Calcium antagonists have antihypertensive and antianginal properties. In heart failure, however, their use can be hazardous, as systolic function can deteriorate. This may nor be true of the new calcium antagonist mibefradil, which has a new chemical structure. Calcium antagonists may also be beneficial for diastolic left ventricular function in coronary artery disease. To investigate the possible effects of mibefradil on diastolic left ventricular function, we performed the present study as a multicenter, double-blind, placebo-controlled, multiple-dose safety trial. Fifteen patients with New York Heart Association (NYHA) class II or III for dyspnea and depressed ejection fraction (

Original languageEnglish
Pages (from-to)652-656
Number of pages5
JournalJournal of Cardiovascular Pharmacology
Issue number5
Publication statusPublished - May-1996


  • calcium antagonists, mibefradil, Heart failure, diastolic function, CALCIUM-ANTAGONIST, STABLE ANGINA, DYSFUNCTION, MECHANISMS, RO-40-5967

ID: 6463545